Aquestive Therapeutics (AQST) PT Lowered to $26 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Price: $4.61 +0.88%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 3
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 3
Join SI Premium – FREE
Wedbush analyst Liana Moussatos lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $26.00 (from $28.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Reckitt Benckiser (RKT:LN) (RBGLY) to Buy
- Heidelberg Materials AG (HEI:GR) (HDELY) PT Lowered to EUR210 at Deutsche Bank
- Veolia Environnement SA (VIE:FP) (VEOEY) PT Lowered to EUR37 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
